What is Brief History of Ipsen Company?

What is the history of Ipsen?

Ipsen S.A. is a global biopharmaceutical company focused on innovation and specialty care. Founded in 1929 by Henri Beaufour in France as Laboratoires Beaufour, it began as a small pharmaceutical entity.

The company's journey includes strategic acquisitions, such as Onivyde in 2015 for approximately 400 million euros, significantly bolstering its oncology offerings.

What is Brief History of Ipsen Company?

Ipsen, now publicly traded on Euronext Paris (IPN), boasts a market capitalization of $10.9 billion as of July 28, 2025, with 82.8 million shares outstanding. It ranks among the top 15 biopharmaceutical companies globally for oncology sales. The company's strategic focus has evolved to three core therapeutic areas: Oncology, Neuroscience, and Rare Diseases, a notable shift from its initial ventures into consumer healthcare and treatments for digestive and neurological issues. This transformation highlights Ipsen's growth from a family business to a worldwide leader in specialty care, with products like those analyzed in the Ipsen BCG Matrix.

The Ipsen company history began in 1929 when Henri Beaufour established Laboratoires Beaufour in France. This small pharmaceutical enterprise was built on a foundation of developing prescription-based products, marking the start of a long journey in the healthcare sector. The founding vision was to create innovative treatments, laying the groundwork for what would become a significant global entity.

Ipsen's Founding Story

The Ipsen company origins trace back to 1929 with the founding of Laboratoires Beaufour by Henri Beaufour in France. Initially, the focus was on creating prescription drugs, a model that guided its early development. This period set the stage for the company's future growth and its eventual transformation into a global specialty care leader.

• Founded in 1929 by Henri Beaufour as Laboratoires Beaufour.
• Initial business model focused on discovery, development, manufacturing, and marketing of prescription drugs.
• An early product was betaine citrate, launched in 1954 for dyspepsia.
• The Beaufour family has maintained significant ownership for over 90 years.

The Beaufour family's enduring involvement has been a cornerstone of the company's trajectory. Henri Beaufour's sons, Albert and Gérard Beaufour, played crucial roles in advancing the enterprise. This familial stewardship has ensured a consistent vision and commitment over decades. The family's substantial stake, owning 57% of shares and 73% of voting rights, underscores their continued influence, with two family members presently serving on the board of directors. This deep-rooted ownership has been instrumental in shaping the company's strategic direction and its approach to innovation, a key aspect of its Marketing Strategy of Ipsen.

A notable early product that exemplified the company's commitment to therapeutic solutions was betaine citrate, introduced in 1954. This medication was developed for the symptomatic treatment of dyspepsia, addressing a common gastrointestinal ailment. The success and development of such products during its nascent stages were vital for establishing the company's reputation and market presence. The evolution of the company included a significant rebranding, with Laboratoires Beaufour officially changing its name to Ipsen in 2003. This name change coincided with its public listing on the Paris Stock Exchange (Euronext) in 2005, marking a new chapter of transparency and broader market engagement.

Complete Ipsen Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

The Ipsen company history began with its founding in 1929 as Laboratoires Beaufour, marking the start of a journey focused on pharmaceutical development and expansion. This early period laid the groundwork for its future growth and international presence.

Foundational Infrastructure Development

Following its establishment, the company focused on building its operational capacity. A significant step was the opening of a factory in Dreux in 1961, followed by another in L'Isle-sur-la-Sorgue in 1965. The same year, a dedicated research center was established in Plessis-Robinson, underscoring an early commitment to innovation.

Internationalization and Product Innovation

The 1970s and 1980s saw a strategic push towards international markets, with the creation of the Ipsen subsidiary in 1975. This era also witnessed key product introductions, such as Smecta in 1977 and Decapeptyl in 1986. The establishment of a research center in Milford, Massachusetts, in 1976 further solidified its global R&D footprint.

Diversification and Global Reach Expansion

The 1990s were characterized by continued diversification and expansion into new territories, including Russia in 1994 and China in 1992. This period was marked by the successful launch of significant products like Dysport in 1994, Somatuline in 1995, and Forlax in 1996, broadening the company's therapeutic offerings.

Strategic Realignment and Specialty Focus

Leadership transitioned to Albert Beaufour's children, Anne and Henri Beaufour, in 2000. A significant rebranding in 2005 aimed to unify its global identity. The company strategically shifted its focus to specialty care, particularly in oncology, neuroscience, and rare diseases, a direction reinforced by the divestment of its consumer healthcare business in July 2022, which represented 8% of its 2021 revenue. This move allowed for increased investment in its core therapeutic areas, aligning with its Mission, Vision & Core Values of Ipsen.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Ipsen company history is characterized by strategic advancements, groundbreaking innovations, and adept navigation of market challenges. From its early product launches to significant acquisitions in the 2010s and 2020s, the company has consistently aimed to expand its therapeutic reach and strengthen its market position.

Ipsen's innovation is evident in its development and strategic acquisition of novel therapies. The company's commitment to advancing patient care is showcased through products like Somatuline and Dysport, which have become significant treatments in their respective fields.

Somatuline Development

Launched in 1995, Somatuline addresses acromegaly and neuro-endocrine tumors, later securing U.S. market approval in 2007.

Dysport Application

Introduced in 1994, Dysport, a botulinum toxin, expanded its applications to both therapeutic and aesthetic uses, gaining U.S. authorization in 2007.

Cabozantinib Licensing

In 2016, the company licensed cabozantinib, a significant move that led to its marketing authorization for advanced renal cell carcinoma.

Rare Disease Portfolio Expansion

Strategic acquisitions of Clementia Pharmaceuticals in 2019 and Albireo Pharma in 2023 significantly bolstered its rare disease pipeline with promising treatments.

Oncology Portfolio Enhancement

The 2017 acquisition of Merrimack Pharmaceuticals' assets, including Onivyde, marked a substantial expansion of its oncology offerings.

Tazverik Acquisition

The 2022 acquisition of Epizyme brought Tazverik into the company's portfolio, targeting follicular lymphoma.

The company has faced challenges including generic competition for key products and regulatory hurdles, such as the FDA's clinical hold on palovarotene. These situations have prompted strategic adjustments, including a focus on diversifying revenue streams and prioritizing external innovation to maintain growth and strengthen its business model.

Generic Competition Impact

The emergence of generic alternatives for established products like Somatuline has presented a significant challenge, necessitating a focus on newer revenue sources.

Regulatory Setbacks

A clinical hold placed by the FDA on palovarotene created market uncertainty and impacted the company's share performance.

Strategic Realignment

In response to market dynamics, the company initiated an 'Efficiency for Growth' program, aiming to reduce SG&A expenses by 3.5% through operational streamlining.

Leadership Transition

The appointment of CEO David Loew during a critical period signaled a strategic shift towards focusing on specialty care and rebalancing the research and development pipeline.

Pipeline Rebalancing

A key strategic imperative has been to rebalance the R&D pipeline, emphasizing external innovation to complement internal development efforts.

Focus on Specialty Care

The company has strategically pivoted to concentrate on specialty care areas, aiming to leverage its expertise and market presence more effectively.

Ipsen Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

The Ipsen company history is a narrative of consistent innovation and strategic expansion, beginning in 1929. From its origins as Laboratoires Beaufour, the company has evolved into a significant player in the global pharmaceutical landscape, marked by key product launches and strategic acquisitions that have shaped its trajectory. This journey reflects a deep commitment to advancing healthcare solutions.

Financial Performance and Growth Projections

For 2025, Ipsen anticipates total sales growth greater than 5.0% at constant currency. The company projects a core operating margin exceeding 30.0% of total sales.

Pipeline Advancement and Key Milestones

Ipsen is focused on advancing its pipeline with key milestones expected in 2025. These include the first data readout for the Long-Acting Neurotoxin (LANT) and regulatory decisions for Cabometyx in the EU.

Rare Diseases Portfolio as a Growth Driver

The Rare Diseases portfolio is a significant growth driver for Ipsen, with sales surging 74.6% at constant exchange rates in Q1 2025. This segment now accounts for nearly half of total sales growth.

Strategic Focus and Sustainability Goals

Ipsen aims to sustain growth through a diversified portfolio, strategic acquisitions, and R&D investment. The company also prioritizes sustainability, targeting emission reductions by 2030, aligning with its Growth Strategy of Ipsen.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE